Myelin, Oligodendrocyte Glycoprotein (OMgp, MOG)

MOG peptide (35-55) is highly encephalitogenic and can induce strong T and B cell responses. A single injection of this peptide produces a relapsing- remitting neurologic disease with extensive plaque-like demyelination. Because of the clinical, histophathologic, and immunologic similarities with multiple sclerosis (MS), the MOG induced demyelinating encephalomyelitis may serve as a model for investigating MS.\n\nMOG is a single, non-glycosylated polypeptide chain containing 21 amino acids and having a molecular mass of 2582 Dalton.\n\nAmino Acid Sequence: H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH.\n\nDimers and Aggregates: \n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm.\n2. Analysis by RP-HPLC, using a calibrated solution of MOG as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute by adding ddH2O and a carrier protein (0.1% HSA or BSA). Aliquot and store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M9758-08D

Size

5mg

Form

Supplied as a lyophilized powder without additives. Reconstitution: Reconstitute with ddH2O to 100ug/ml. Further dilutions can be made in assay buffer.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Quantitation of myelin oligodendrocyte glycoprotein and myelin basic protein in the thymus and central nervous system and its relationship to the clinicopathologic features of autoimmune encephalomyelitis. J Neurosci Res (2006) Jun 13. 2. Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis. Clin Neurol Neurosurg (2006) Jun 1. 3. Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments. J Neuroimmunol (2006) May;174(1-2):147-56. 4. Persistence of autoreactive myelin oligodendrocyte glycoprotein (MOG)-specific T cell repertoires in MOG-expressing mice. Eur J Immunol (2006) Mar;36(3):533-43. 5. Organ specific autoantigens and the autoreactiveT cell repertoire: the case of myelin oligodendrocyte glycoprotein. Eur J Immunol (2006) Mar;36(3):512-5. 6. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA (2006) Feb 14;103(7):2280-5.